This selection closely aligned with the tumour spectrum of the p53 KO model, characterised by a median tumour onset occurring at 4.5 months, with immune tumours being the predominant type, followed by stromal tumours, while epithelial tumours are rarely observed.1, 68, 69, 70, 71. Here, TP53 is linked to neoplasm.